Delivery of hypericin for photodynamic applications

Cancer Letters

Volumn 241, Issue 1, 2006, Pages 23-30

  Saw, Constance Lay Lay ^a   Olivo, Malini ^b   Soo, Khee Chee ^b   Heng, Paul Wan Sia ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

5 Aminolevulinic acid; Cancer detection; Delivery; Fluorescence endoscopy; Hexaminolevulinate; Hypericin; Photodynamic; Photosensitizer; Uptake mechanism

Indexed keywords

DRUG DERIVATIVE; FLUORESCENT DYE; HYPERICIN; PERYLENE; PHOTOSENSITIZING AGENT;

ANIMAL; HUMAN; PHOTOCHEMOTHERAPY; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; FLUORESCENT DYES; HUMANS; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SENSITIVITY AND SPECIFICITY;

EID: 33846530266     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.10.020     Document Type: Review

References (68)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics. Cancer J. Clin. 2005, 55:10-30.
2. Borden L.S., Clark P.E., Hall M.C. Bladder cancer. Curr. Opin. Oncol. 2003, 15:227-233.
3. A. Seow, W.P. Koh, K.S. Chia, L.M. Shi, H.P. Lee, K. Shanmugaratnam, Trends in cancer incidence in Singapore 1968-2002, Singapore Cancer Registry Report No. 6, 2004, p. 132.
4. Jichlinski P. New diagnostic strategies in the detection and staging of bladder cancer. Curr. Opin. Urol. 2003, 13:351-355.
5. Jichlinski P., Leisinger H.J. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist!. Urol. Int. 2005, 74:97-101.
6. D'Hallewin M.A., De Witte P.A., Waelkens E., Merlevede W., Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J. Urol. 2000, 164:349-351.
7. Sim H.G., Lau W.K.O., Olivo M., Tan P.H., Cheng C.W.S. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma?. BJU Int. 2005, 95:1215-1218.
8. Kriegmair M., Ehsan A., Baumgartner R., Lumper W., Knuechel R., Hofstadter F., et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994, 44:836-841.
9. Jichlinski P., Forrer M., Mizeret J., Glanzmann T., Braichotte D., Wagnieres G., et al. Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg. Med. 1997, 20:402-408.
10. Koenig F., McGovern F.J., Larne R., Enquist H., Schomacker K.T., Deutsch T.F. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int. 1999, 83:129-135.
11. Lange N., Jichlinski P., Zellweger M., Forrer M., Marti A., Guillou L., et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br. J. Cancer 1999, 80:185-193.
12. Jichlinski P., Guillou L., Karlsen S.J., Malmstrom P.U., Jocham D., Brennhovd B., et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer-a multicenter study. J. Urol. 2003, 170:226-229.
13. D'Hallewin M.A., Kamuhabwa A.R., Roskams T., De Witte P.A., Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int. 2002, 89:760-763.
14. Agostinis P., Vantieghem A., Merlevede W., De Witte P.A. Hypericin in cancer treatment: more light on the way. Int. J. Biochem. Cell Biol. 2002, 34:221-241.
15. Kriegmair M., Baumgartner R., Knuchel R., Stepp H., Hofstadter F., Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996, 155:105-109. (discussion 109-110).
16. D'Hallewin M.A., Bezdetnaya L., Guillemin F. Fluorescence detection of bladder cancer: a review. Eur. Urol. 2002, 42:417-425.
17. Brunner H., Hausmann F., Krieg R.C., Endlicher E., Scholmerich J., Knuechel R., et al. The effects of 5-aminolevulinic acid esters on protoporphyrin IX production in human adenocarcinoma cell lines. Photochem. Photobiol. 2001, 74:721-725.
18. Uehlinger P., Zellweger M., Wagnieres G., Juillerat-Jeanneret L., van den Bergh H., Lange N. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J. Photochem. Photobiol. B 2000, 54:72-80.
19. Novo M., Huttmann G., Diddens H. Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. J. Photochem. Photobiol. B 1996, 34:143-148.
20. Marti A., Lange N., van den Bergh H., Sedmera D., Jichlinski P., Kucera P. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J. Urol. 1999, 162:546-552.
21. Cosserat-Gerardin I., Bezdetnaya L., Notter D., Vigneron C., Guillemin F. Biosynthesis and photodynamic efficacy of protoporphyrin IX (PpIX) generated by 5-aminolevulinic acid (ALA) or its hexylester (hALA) in rat bladder carcinoma cells. J. Photochem. Photobiol. B 2000, 59:72-79.
22. Zaak D., Karl A., Knuchel R., Stepp H., Hartmann A., Reich O., et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int. 2005, 96:217-222.
23. Kamuhabwa A., Agostinis P., Ahmed B., Landuyt W., van Cleynenbreugel B., van Poppel H., et al. Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Photochem. Photobiol. Sci. 2004, 3:772-780.
24. Lavie G., Mazur Y., Lavie D., Meruelo D. The chemical and biological properties of hypericin-a compound with a broad-spectrum of biological-activities. Med. Res. Rev. 1995, 15:111-119.
25. Kubin A., Wierrani F., Burner U., Alth G., Grunberger W. Hypericin-the facts about a controversial agent. Curr. Pharm. Des. 2005, 11:233-253.
26. Koren H., Schenk G.M., Jindra R.H., Alth G., Ebermann R., Kubin A., et al. Hypericin in phototherapy. J. Photochem. Photobiol. B 1996, 36:113-119.
27. Miskovsky P. Hypericin-a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr. Drug Targets 2002, 3:55-84.
28. Schinazi R.F., Chu C.K., Babu J.R., Oswald B.J., Saalmann V., Cannon D.L., et al. Anthraquinones as a new class of antiviral agents against human-immunodeficiency-virus. Antiviral Res. 1990, 13:265-272.
29. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3:380-387.
30. Huygens A., Kamuhabwa A.R., De Witte P.A.M. Stability of different formulations and ion pairs of hypericin. Eur. J. Pharm. Biopharm. 2005, 59:461-468.
31. Huygens A., Kamuhabwa A.R., van Cleynenbreugel B., van Poppel H., Roskams T., De Witte P.A. In vivo accumulation of different hypericin ion pairs in the urothelium of the rat bladder. Brit. J. Urol. Int. 2005, 95:436-441.
32. C.L. Saw, P.W. Heng, W.W. Chin, K.C. Soo, M. Olivo, Enhanced photodynamic activity of hypericin by penetration enhancer N-methyl pyrrolidone formulations in the chick chorioallantoic membrane model, Cancer Lett. (available online 28 July 2005).
33. Saw C.L., Olivo M., Chin W.W., Soo K.C., Heng P.W. Transport of hypericin across chick chorioallantoic membrane and photodynamic therapy vasculature assessment. Biol. Pharm. Bull. 2005, 28:1054-1060.
34. Uzdensky A.B., Bragin D.E., Kolosov M.S., Kubin A., Loew H.G., Moan J. Photodynamic effect of hypericin and a water-soluble derivative on isolated crayfish neuron and surrounding glial cells. J. Photochem. Photobiol. B 2003, 72:27-33.
35. Kamuhabwa A.R., Geboes K.R., De Witte P.A. Investigation of the absorption of hypericin into the skin of hairless mice. J. Pharm. Pharmacol. 2000, 52:487-494.
36. Kamuhabwa A.R., Roelandts R., De Witte P.A. Skin photosensitization with topical hypericin in hairless mice. J. Photochem. Photobiol. B 1999, 53:110-114.
37. Sattler S., Schaefer U., Schneider W., Hoelzl J., Lehr C.M. Binding, uptake, and transport of hypericin by caco-2 cell monolayers. J. Pharm. Sci. 1997, 86:1120-1126.
38. Ebermann R., Alth G., Kreitner M., Kubin A. Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. J. Photochem. Photobiol. B 1996, 36:95-97.
39. Falk H. From the photosensitizer hypericin to the photoreceptor stentorin-the chemistry of phenanthroperylene quinones. Angew. Chem. Int. Ed. Engl. 1999, 38:3116-3136.
40. Falk H., Meyer J., Oberreiter M. A convenient semisynthetic route to hypericin. Monatsh. Chem. 1993, 124:339-341.
41. Derycke A.S.L., De Witte P.A.M. Liposomes for photodynamic therapy. Adv. Drug Deliv. Rev. 2004, 56:17-30.
42. Vargas A., Pegaz B., Debefve E., Konan-Kouakou Y., Lange N., Ballini J.P., et al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int. J. Pharm. 2004, 286:131-145.
43. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37:1590-1598.
44. Konan Y.N., Gurny R., Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B 2002, 66:89-106.
45. Miskovsky P., Sureau F., Chinsky L., Turpin P.Y. Subcellular distribution of hypericin in human cancer cells. Photochem. Photobiol. 1995, 62:546-549.
46. Kamuhabwa A.R., Augustijns P., De Witte P.A. In vitro transport and uptake of protohypericin and hypericin in the Caco-2 model. Int. J. Pharm. 1999, 188:81-86.
47. Chen B., De Witte P.A. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett. 2000, 150:111-117.
48. Andreoni A., Colasanti A., Colasanti P., Mastrocinque M., Riccio P., Roberti G. Laser photosensitization of cells by hypericin. Photochem. Photobiol. 1994, 59:529-533.
49. Chung P.S., Saxton R.E., Paiva M.B., Rhee C.K., Soudant J., Mathey A., et al. Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy. Laryngoscope 1994, 104:1471-1476.
50. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 2001, 1:385-401.
51. Kamuhabwa A.R., Agostinis P., D'Hallewin M.A., Kasran A., De Witte P.A. Photodynamic activity of hypericin in human urinary bladder carcinoma cells. Anticancer Res. 2000, 20:2579-2584.
52. Das K., Smirnov A.V., Wen J., Miskovsky P., Petrich J.W. Photophysics of hypericin and hypocrellin A in complex with subcellular components: interactions with human serum albumin. Photochem. Photobiol. 1999, 69:633-645.
53. Theodossiou T., Spiro M.D., Jacobson J., Hothersall J.S., Macrobert A.J. Evidence for intracellular aggregation of hypericin and the impact on its photocytotoxicity in PAM 212 murine keratinocytes. Photochem. Photobiol. 2004, 80:438-443.
54. Kelbauskas L., Dietel W. Internalization of aggregated photosensitizers by tumor cells: subcellular time-resolved fluorescence spectroscopy on derivatives of pyropheophorbide-a ethers and chlorin e6 under femtosecond one- and two-photon excitations. Photochem. Photobiol. 2002, 76:686-694.
55. Uzdensky A.B., Ma L.W., Iani V., Hjortland G.O., Steen H.B., Moan J. Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines. Lasers Surg. Med. 2001, 16:276-283.
56. Thomas C., Pardini R.S. Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem. Photobiol. 1992, 55:831-837.
57. Weber N.D., Murray B.K., North J.A., Wood S.G. The antiviral agent hypericin has in-vitro activity against Hsv-1 through nonspecific association with viral and cellular membranes. Antivir. Chem. Chemother. 1994, 5:83-90.
58. Huygens A., Kamuhabwa A.R., Roskams T., van Cleynenbreugel B., van Poppel H., De Witte P.A. Permeation of hypericin in spheroids composed of different grade transitional cell carcinoma cell lines and normal human urothelial cells. J. Urol. 2005, 174:69-72.
59. Du H.Y., Bay B.H., Olivo M. Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model. Int. J. Oncol. 2003, 22:1019-1024.
60. Chen B., Roskams T., De Witte P.A. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem. Photobiol. 2002, 76:509-513.
61. Chen B., Roskams T., Xu Y., Agostinis P., De Witte P.A. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int. J. Cancer 2002, 98:284-290.
62. Chen B., Xu Y., Roskams T., Delaey E., Agostinis P., Vandenheede J.R., et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int. J. Cancer 2001, 93:275-282.
63. Chen B., Zupko I., De Witte P.A. Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. Int. J. Oncol. 2001, 18:737-742.
64. Kamuhabwa A.A.R., Cosserat-Gerardin I., Didelon J., Notter D., Guillemin F., Roskams T., et al. Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. Int. J. Cancer. 2002, 97:253-260.
65. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 2003, 61:25-31.
66. Moreau J.P., Vachon P.J., Huneau M.C. Elevated glycemia and local inflammation after injecting N-methyl-2-pyrrolidone (NMP) into the marginal ear vein of rabbits. Contemp. Top. Lab. Anim. Sci. 2001, 40:38-40.
67. Akesson B., Paulsson K. Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): acute effects and pharmacokinetics of NMP in plasma and urine. Occup. Environ. Med. 1997, 54:236-240.
68. Leira H.L., Tiltnes A., Svendsen K., Vetlesen L. Irritant cutaneous reactions to N-methyl-2-pyrrolidone (NMP). Contact Dermatitis 1992, 27:148-150.